Lantern Pharma gets USPTO Notice of Allowance for LP—284
Lantern Pharma received a USPTO Notice of Allowance for a patent covering LP—284 to treat mantle cell lymphoma and double-hit lymphoma, including combo regimens and routes.
Lantern Pharma received a USPTO Notice of Allowance for a patent covering LP—284 to treat mantle cell lymphoma and double-hit lymphoma, including combo regimens and routes.